MedTrace Logo

Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis

NCT02144857 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-05-16

No results posted yet for this study

Summary

Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction and myocardial dysfunction are impaired in patients with psoriasis compared to normal controls ,coronary artery disease patients and untreated hypertension subjects. The investigators also examined the effect of treatment with biological vs no biological agents on vascular and LV function in psoriasis.

Conditions

Interventions

DRUG

etanercept

50 mg

DRUG

ustekinumab

45 mg

DRUG

cyclosporine

Cyclosporine 2.5-3 mg/kgr

DRUG

Secukinumab

300 mg

DRUG

Apremilast

30mg

Sponsors & Collaborators

  • University of Athens

    lead OTHER

Principal Investigators

  • Ignatios Ikonomidis, Dr · University of Athens

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-30
Primary Completion
2023-09-30
Completion
2023-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02144857 on ClinicalTrials.gov